Mediating effect of metabolic diseases on the relationship between hyperuricemia and coronary heart disease.

Nutr Metab Cardiovasc Dis

Department of Epidemiology and Statistics, School of Public Health, Lanzhou University, 199 Donggang West Street, Lanzhou, Gansu 730000, China. Electronic address:

Published: February 2023

Background And Aims: Studies have shown that elevated serum uric acid (SUA) may increase the risk of coronary heart disease (CHD). However, it is still disputable how mediate effects between metabolic diseases and hyperuricemia affect the incidence of CHD. This study aimed to explore whether metabolic diseases may mediate the connection from hyperuricemia at baseline to the elevated incidence risk of CHD during follow-ups.

Methods And Results: Based on the Jinchang cohort, 48 001 subjects were followed for 9 years between June 2011 and December 2019. Multivariate-adjusted Cox regression models were applied to estimate hazard ratios (HRs) of CHD with 95% confidence intervals (CIs). Significantly increased risks of CHD were observed in hyperuricemia (HR:1.46, 95%CI:1.28, 1.67) when compared with normouricemia population. The mediating effect model further demonstrated that metabolic diseases could mediate the association between hyperuricemia and CHD pathogenesis, partially for the combined metabolic diseases with mediation effects of 45.12%, 25.24% for hypertension, 28.58% for overweight or obese status, 29.05% for hypertriglyceridemia, 6.70% for hypercholesterolemia, 3.52% for low high density lipoprotein cholesterol (HDL-C), and 6.51% for high low density lipoprotein cholesterol (LDL-C), respectively.

Conclusions: Hyperuricemia significantly increased the risk of incident CHD, and this association was partly mediated by metabolic diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.numecd.2022.11.005DOI Listing

Publication Analysis

Top Keywords

metabolic diseases
24
coronary heart
8
heart disease
8
diseases mediate
8
density lipoprotein
8
lipoprotein cholesterol
8
chd
7
diseases
6
hyperuricemia
6
metabolic
5

Similar Publications

Effect of cognitive-behavioral therapy on fatigue in cancer patients: a systematic review and meta-analysis.

Front Psychol

January 2025

Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.

Background: Fatigue is a prevalent issue among cancer patients. Cognitive behavioral therapy (CBT) is an individualized intervention that empowers patients and caregivers to actively participate in the treatment process. A recent systematic review and meta-analysis examined the impact of CBT on fatigue in cancer patients.

View Article and Find Full Text PDF

Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease.

J Inflamm Res

January 2025

Department of Infectious Disease, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People's Republic of China.

Chronic liver disease ranks as the 11th leading cause of death worldwide, while hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality, representing a substantial risk to public health. Over the past few decades, the global landscape of chronic liver diseases, including hepatitis, metabolic dysfunction-associated steatotic liver disease (MASLD), liver fibrosis, and HCC, has undergone substantial changes. Copper, a vital trace element for human health, is predominantly regulated by the liver.

View Article and Find Full Text PDF

Objective: In this study, it was aimed to screen fatty liver in individuals with metabolic disorders, and to investigate the use of some anthropometric calculations and body composition indices in demonstrating fatty liver disease.

Methods: The cross-sectional study included 224 participants with metabolic diseases. Anthropometric measurements of the participants were measured.

View Article and Find Full Text PDF

Proton pump inhibitors and all-cause mortality risk among cancer patients.

World J Clin Oncol

January 2025

Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC 28204, United States.

Background: Proton pump inhibitors (PPIs) are widely used, including among cancer patients, to manage gastroesophageal reflux and other gastric acid-related disorders. Recent evidence suggests associations between long-term PPI use and higher risks for various adverse health outcomes, including greater mortality.

Aim: To investigate the association between PPI use and all-cause mortality among cancer patients by a comprehensive analysis after adjustment for various confounders and a robust methodological approach to minimize bias.

View Article and Find Full Text PDF

Interplay between energy metabolism and NADPH oxidase-mediated pathophysiology in cardiovascular diseases.

Front Pharmacol

January 2025

Department of Emergency Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Sustained production of reactive oxygen species (ROS) and an imbalance in the antioxidant system have been implicated in the development of cardiovascular diseases (CVD), especially when combined with diabetes, hypercholesterolemia, and other metabolic disorders. Among them, NADPH oxidases (NOX), including NOX1-5, are major sources of ROS that mediate redox signaling in both physiological and pathological processes, including fibrosis, hypertrophy, and remodeling. Recent studies have demonstrated that mitochondria produce more proteins and energy in response to adverse stress, corresponding with an increase in superoxide radical anions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!